A New Way In: How Outside-the-box Science Sparked a Revolution in Targeting KRAS
At the recent AACR Conference on Pancreatic Cancer, Kevan M. Shokat, PhD, FAACR, received the 2026 Stephenson Global Prize...
Tag: KRAS
At the recent AACR Conference on Pancreatic Cancer, Kevan M. Shokat, PhD, FAACR, received the 2026 Stephenson Global Prize...
The AACR Annual Meeting 2025, held April 25-30, featured six Plenary Sessions that explored exciting areas of cancer research,...
Understanding pancreatic cancer’s strengths may provide clues to its weaknesses.
This Trojan horse-like treatment strategy may help neutralize undruggable cancer drivers.
Outside the lab, Frank McCormick, PhD, FAACR, is a racecar driver, nurturing a passion he developed decades ago. (“We...
Once considered undruggable, mutant KRAS has emerged in recent years as a viable target for anticancer therapeutics. As a...
After three decades of failed efforts to target the elusive KRAS and its family members NRAS and HRAS, proto-oncogenes...